Resumen
This review summarizes the current findings about the cellular roles of protein arginine methyltransferases (PRMTs) in the formation of blood cells from stem cell progenitors and in different blood cancers such as leukemia and lymphoma. The work also provides a substantial insight into the development and the use of PRMT inhibitors for the treatment of hematological cancers. This review aims to show the research community that targeting PRMTs could be a novel and promising therapeutic approach for these diseases.